<DOC>
	<DOCNO>NCT00793897</DOCNO>
	<brief_summary>A Phase I dose escalation study determine safety , tolerability , pharmacodynamics preliminary anti-tumor activity BMS-754807 combination chemotherapy drug , paclitaxel carboplatin , patient advance metastatic solid tumor . In addition , study expect identify recommend dose dose range BMS-754807 combination paclitaxel carboplatin Phase 2 study</brief_summary>
	<brief_title>Multiple Dose Study In Cancer Patients : Safety Tolerability BMS-754807 Combination With Paclitaxel Carboplatin Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Subjects advance metastatic solid tumor carboplatin paclitaxel consider appropriate therapy ECOG performance status 01 At least 4 week surgery last dose prior anticancer therapy Symptomatic brain metastases Any disorder dysregulation glucose homeostasis { e.g . diabetes ) Uncontrolled significant cardiovascular disease Inadequate bone marrow , liver kidney function Evidence &gt; Grade 1 peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Subjects Advanced Metastatic Solid Tumors Neoplasms</keyword>
</DOC>